PH-109 / Phio Pharma - LARVOL DELTA

Intratumoral PH-109 INTASYL™ self-delivering RNAi targeting connective tissue growth factor (CTGF) provides efficacy in vivo in a mouse model of metastatic breast cancer (SITC 2022) - P1/2, P2a | "Vehicle (PBS), a chemically-identical non-targeting control (NTC) INTASYL or PH-109 at two dose concentrations (0.5 mg; 2 mg) were administered IT; doxorubicin chemotherapy (5 mg/kg) was administered intraperitoneally on Days 1, 7, 13. This, combined with these data in a clinically relevant orthotopic mouse model of metastatic breast cancer, could support accelerated clinical investigation of PH-109 as an anticancer therapeutic. Ethics Approval Animal studies were performed at Pharma Models LLC, Marlborough, MA 01752, under standard protocol approved by their IACUC."

Preclinical • Breast Cancer • Oncology • Solid Tumor • CTGF

Phio Pharmaceuticals Announces Study Results at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on November 10th and 11th (PRNewswire) - 'Phio Pharmaceuticals...announced the results of several studies of its INTASYL™ compounds....The posters will be presented on November 10th and 11th at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which is being held in Boston, MA from November 8 – 12, 2022."

P1 data • Preclinical • Breast Cancer • Melanoma • Oncology • Solid Tumor

Phio Pharmaceuticals Announces Upcoming Presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (PRNewswire) - "Phio Pharmaceuticals...announced it is scheduled to provide an update on its programs at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will be held in Boston, MA from November 8 - 12, 2022. This will include an update on its first-in-human clinical trial with PH-762 in advanced melanoma; data demonstrating the potential of PH-762 to further enhance the function of tumor infiltrating lymphocytes (TILs) with its partner AgonOx, Inc.; and new preclinical data on relevant targets identified in cancer immunotherapy using our INTASYL compounds."

P1 data • Preclinical • Breast Cancer • Melanoma • Oncology • Skin Cancer • Solid Tumor